In 2025, 1 billion of the world population is considered to experience anxiety and depression, and 32% of college students in the U.S. experience moderate-severe anxiety and 18% have severe depression. Common interventions such as medication and CBT are effective in most cases but turn out to fail 50 percent because of its side effects. Mindfulness-based counseling (MBSR/MBCT) applies basic...
This article presents the study of an experimental methodology for the management of anxiety and depression based on Amit Goswami's quantum worldview, addressing the disorders of the mental, physical and vital levels to be worked also at the supramental level, where the creative process occurs through the attribution of new meanings to conditioned beliefs and patterns.The operational protocol...
Women diagnosed with endometriosis often experience heightened anxiety, depression, and a diminished quality of life (QoL). To address these issues, mindful breathing exercises have been introduced aimed at reducing anxiety and depression and enhancing overall QoL. This study aims to evaluate the levels and differences in anxiety, depression, and QoL among women with endometriosis before and...
Treatment-resistant depression (TRD) poses a serious challenge to psychopharmacology, as many patients do not achieve remission despite available therapies. The persistence and recurrence of the disease in the absence of response to antidepressant treatment highlight the complex and multifactorial nature of the disease, including the dysregulation of biological processes such as oxidative...
NeuropsychobiologyFebruary 5, 2026Lavanya Seth, Jitendriya Biswal, Surjeet Sahoo et al.
Severe depressive episodes with suicidal ideation present major therapeutic challenges and often require interventions beyond standard antidepressant therapy. Electroconvulsive therapy (ECT) remains a cornerstone treatment for refractory depression, while ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a rapid-acting antidepressant with potential benefits in...
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown significant promise for the treatment of mental health conditions in recent clinical trials. Organizations such as the National Network of Depression Centers (NNDCs) can play a pivotal role in uniting researchers and clinicians working in this field...
Psychiatry ResearchFebruary 4, 2026Waseem Abu-Ashour, Rick Audas, John-Michael Gamble et al.
Background: Major depressive disorder (MDD) is a chronic condition with high relapse rates affecting patients and health systems. Cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) are strategies for relapse prevention, but their comparative long-term cost-effectiveness remains unclear. Methods: We developed a cohort-based Markov model with three health states,...
Ketamine is known to be a rapid-acting antidepressant, but there is limited evidence regarding which types of patients are best-suited to this treatment and whether adjunctive psychotherapy improves outcomes. In a sample of 224 patients who received five ketamine infusions at a private clinic, this study uses Bayesian mixed modeling to examine the effects of early life stress (measured with the...
PROMOTORFebruary 2, 2026Ni Made Saithanya Gitanjali Dhevi, Rofi Bramantyo, Septy Rianty Salsabilla Dwi Putri et al.
Depression is a psychological disorder that affects aspects of affection, physiology, cognition, and individual behavior, and has an impact on significant changes in daily life. Data from the Ministry of Health of the Republic of Indonesia (2023) shows a national prevalence of depression of 1.4%, with the age group of 15-24 years recording the highest rate of 2%. One approach that is considered...
Major Depressive Disorder is a common and disabling psychiatric illness whose pharmacological treatment options have historically been characterized by relatively low response rates. "Treatment-resistant depression" has emerged to describe patients whose depressive symptoms fail to respond to multiple courses of oral antidepressant medications. In 2019, the FDA approved intranasal esketamine as...